Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	29.62	35.44	11.36	55.74	32.59	9.5
Short-Term Investments	8.87	0.05	46.52	2.62	8.98	21.22
Cash & Short-Term Investments	38.5	35.49	57.88	58.36	41.56	30.72
Cash Growth	-16.18%	-38.67%	-0.83%	40.41%	35.31%	-0.08%
Accounts Receivable	0.24	0.75	0.3	50.84	0	0.32
Receivables	0.24	0.75	0.3	50.84	0	23.94
Prepaid Expenses	1.66	2.18	1.83	2.35	2.36	2.86
Restricted Cash	-	-	-	-	0.08	-
Other Current Assets	-	0.02	-	-	-	-
Total Current Assets	40.39	38.44	60	111.55	44	57.52
Property, Plant & Equipment	4.6	4.77	5.67	4.87	5.63	8.18
Goodwill	10.67	10.67	10.67	10.67	10.67	10.67
Other Intangible Assets	46.54	46.56	46.69	46.82	47.03	48.25
Other Long-Term Assets	0.6	0.58	0.63	0.63	0.62	0.86
Total Assets	102.8	101.02	123.66	174.55	107.95	125.48
Accounts Payable	2.39	2.05	2.39	3.54	2.61	2.43
Accrued Expenses	2.63	4.22	6.22	24.25	3.67	2.8
Short-Term Debt	-	-	-	-	0.52	-
Current Portion of Leases	1.12	0.88	0.95	0.83	0.76	1.22
Current Unearned Revenue	9.14	10.81	9.42	18.12	0.19	0.05
Other Current Liabilities	-	-	-	0.38	0.01	0
Total Current Liabilities	15.28	17.96	18.98	47.12	7.77	6.49
Long-Term Leases	1.84	2.07	2.94	1.97	2.54	3.95
Long-Term Unearned Revenue	18.54	18.69	27.73	32.45	-	0.2
Long-Term Deferred Tax Liabilities	0.27	0.27	2.08	2.08	2.08	3.32
Other Long-Term Liabilities	-	-	0	0.03	0.44	0.28
Total Liabilities	35.93	39	51.73	83.65	12.82	14.23
Common Stock	467.93	451.34	440.28	434.53	393.94	387.06
Retained Earnings	-397.16	-384.86	-363.37	-337.1	-294.08	-273.42
Comprehensive Income & Other	-2.47	-3.07	-3.57	-5.21	-3.67	-0.68
Total Common Equity	68.3	63.42	73.34	92.22	96.2	112.96
Minority Interest	-1.43	-1.4	-1.4	-1.32	-1.07	-1.71
Shareholders' Equity	66.88	62.02	71.94	90.9	95.13	111.25
Total Liabilities & Equity	102.8	101.02	123.66	174.55	107.95	125.48
Total Debt	2.95	2.95	3.9	2.8	3.83	5.17
Net Cash (Debt)	35.55	32.54	53.98	55.56	37.74	25.55
Net Cash Growth	-16.41%	-39.72%	-2.84%	47.22%	47.71%	-10.28%
Net Cash Per Share	0.20	0.19	0.32	0.34	0.25	0.18
Filing Date Shares Outstanding	188.84	188.53	170.15	169.71	161.64	149.81
Total Common Shares Outstanding	188.82	174.99	170.09	169.48	153.1	149.8
Working Capital	25.12	20.48	41.02	64.43	36.23	51.03
Book Value Per Share	0.36	0.36	0.43	0.54	0.63	0.75
Tangible Book Value	11.09	6.19	15.98	34.73	38.5	54.04
Tangible Book Value Per Share	0.06	0.04	0.09	0.20	0.25	0.36
Machinery	3.63	3.61	3.26	3.47	3.63	4.15
Leasehold Improvements	2.23	2.31	2.15	2.54	2.47	2.86

Source: S&P Capital IQ. Standard template. Financial Sources.